• News
  • SAN DIEGO
  • BioTech

Halozyme narrows net loss in 2Q

San Diego-based Halozyme Therapeutics Inc. (Nasdaq: HALO) reported a second quarter net loss of $16.3 million, or $0.13 per share, compared to a net loss of $22.9 million, or $0.20 per share, for the second quarter of 2013.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!